Positron Emission Tomography Using [18F]-Labeled Substance P Antagonist Receptor Quantifier in Finding Disease in Patients With Pancreatic Cancer

National Institutes of Health Clinical Center (CC)33 enrolled

Overview

RATIONALE: Diagnostic procedures, such as positron emission tomography (PET) using \[18F\]-labeled substance P antagonist receptor quantifier, may be effective in finding disease in patients with pancreatic cancer. PURPOSE: This phase I trial is studying how well a PET scan using \[18F\]-labeled substance P antagonist receptor quantifier works in finding disease in patients with pancreatic cancer.

OBJECTIVES: * Determine whether \[18F\]-labeled substance P antagonist receptor quantifier positron emission tomography can identify pancreatic cancer evident on multiphase CT scan. OUTLINE: Patients undergo multiphase CT scan of the chest, abdomen, and pelvis. No more than 15 days later, patients receive \[18F\]-labeled substance P antagonist receptor quantifier IV and undergo positron emission tomography over 6 hours. Blood is collected periodically to measure the metabolism of the radiotracer by high performance liquid chromatography with radioactive detectors.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Enrollment

Conditions

Pancreatic Cancer

Interventions

high performance liquid chromatographyOTHER

pharmacological studyOTHER

[18F]-labeled substance P antagonist receptor quantifierRADIATION

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

DISEASE CHARACTERISTICS: * Histologically confirmed adenocarcinoma of the pancreas * Primary or metastatic disease * At least one site of measurable disease * Enrolled in an NCI protocol (either a treatment or screening protocol) such as NCI-05-C-0044 or NCI-05-C-0141 PATIENT CHARACTERISTICS: Inclusion criteria: * ECOG performance status 0-2 * WBC ≥ 1,200/mm³ * Creatinine \< 2.0 mg/dL * Negative pregnancy test * Fertile patients must agree to use effective contraception * Not pregnant or nursing Exclusion criteria: * Allergy to IV contrast * Claustrophobia that would preclude completion of a scan or unable to lie on one's back for positron emission tomography scan PRIOR CONCURRENT THERAPY: Inclusion criteria: * More than 4 weeks since prior abdominal surgery Exclusion criteria: * Prior participation in other research protocols within the past year such that a radiation exposure together with the present study would exceed the annual limits * Aprepitant within 72 hours of \[18F\]-labeled substance P antagonist receptor quantifier positron emission tomography

Locations (1)

Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office

Bethesda, Maryland, United States

Outcomes

Primary Outcomes

Proportion of tumors detected by [18F]-labeled substance P antagonist receptor quantifier positron emission tomography

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.